Accuray Announces Approval of the Tomo® C Radiation Treatment Delivery System by China's National Medical Products Administration
"The NMPA approval of the Tomo C System represents a tremendous milestone for
The Tomo C platform features helical imaging and radiation delivery. With fully-integrated treatment planning, centralized data management and ultra-precise treatment delivery using patented beam-shaping technology, the system enables greater control of the radiation dose so it conforms precisely to the tumor and helps minimize dose to healthy tissue. The system's unique architecture and high-speed multi-leaf collimator makes it possible for medical care teams to select from a range of delivery modalities, from conventionally fractionated to ultra-hypofractionated treatments, to optimize outcomes for standard radiation therapy indications including breast, prostate, lung, and head and neck cancers, in addition to complex treatments such as total marrow irradiation.
About
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expectations and goals regarding new products, services and innovations, expectations regarding our joint venture, patient experiences and patient outcomes. These risks and uncertainties include, but are not limited to, the effect of the current global economic environment, including in connection to the COVID-19 pandemic, on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands; reliance on third party collaborators, partnerships, strategic alliances and joint ventures; and such other risks identified under the heading "Risk Factors" in the company's Annual Report on Form 10-K, filed with the
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contact:
Public Relations Director,
+1 (408) 789-4426
bkaplan@accuray.com
1 https://www-pub.iaea.org/MTCD/Publications/PDF/P1638_web.pdf
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-announces-approval-of-the-tomo-c-radiation-treatment-delivery-system-by-chinas-national-medical-products-administration-301944172.html
SOURCE